Abstract: The present invention relates to the field of structural biology. More specifically, the present invention relates to an antigen-binding chimeric protein, called a MegaBody™, specifically binding a nanodisc, more specifically a membrane-scaffold protein (MSP)n which may be part of the nanodisc. The invention further provides for methods and uses of said nanodisc-specific antigen-binding chimeric proteins in three-dimensional high-resolution structural analysis of membrane proteins assembled within nanodiscs. The MSP-binding MegaBodies of the invention provide for a generic tool in membrane protein structural biology, more particular in Cryo-EM, by reducing preferred particle orientation of nanodiscs and of the entrapped target membrane proteins.

Abstract: Described herein is a composition of two or more bacterial strains, wherein the composition comprises a bacterial strain of at least two of the following genera: Phascolarctobacterium, Veillonella, Eubacterium, Agathobacter, Lactiplantibacillus, and Anaerostipes. Aspects and embodiments described herein may be used in the treatment of joint inflammation, symptoms thereof, and underlying diseases and conditions.

Abstract: The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses means and methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agent. Said cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics of said reaction.

Abstract: Provided is a method of characterising a polynucleotide using a transmembrane pore, wherein the pore is a double pore comprising a first Csg G pore, or a homologue thereof, and a second CsgG pore, or a homologue thereof.

Abstract: The present disclosure relates to spiro-fused tetrahydroquinazoline compounds, to the compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of diseases comprising the use of the compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the compounds as well as to compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of compounds.

Abstract: The present invention is in the field of agricultural pathogen control. More specifically the invention relates to methods and compounds for controlling herbivorous arthropods, in particular insects and mites. The invention also provides for compositions comprising the same, methods of making the same, and methods of controlling plant disease.

Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.

Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Abstract: The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-?) and methods of treatment using such compositions.

Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.

Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

Abstract: The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.

Abstract: The present invention relates, in part, to chimeric proteins comprising a modified human IFN-? having one or more mutations that confer reduced affinity and/or biological activity that is restorable by attachment to one or more targeting moieties. The one or more targeting moieties may have recognition domains which specifically bind to antigens or receptors of a tumor or an immune cell. The one or more recognition domains may be a single-domain antibody or a single-chain antibody (scFv). The application also provides use of the chimeric proteins as therapeutic agents.

Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

Abstract: The present application provides glycosylation engineered higher eukaryotic cells which produce homogeneous forms of sialylated glycans present on a recombinant glycoprotein. In particular, the glycosylation engineered higher eukaryotic cells produce homogeneous forms of small N-glycan structures which carry terminal sialic acid residues. In addition, the invention provides glycan-conjugates based on specific coupling with sialic acid residues present on the recombinant glycoproteins.

Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.

Abstract: The invention relates to field of cancer therapy. In particular, it relates to (populations of) isolated CD8+ T-cells substantially lacking functional plexin-A2 and/or plexin-A4. Such cells can be employed in e.g. adoptive cell transfer to treat a tumor or cancer.

Abstract: The present invention relates, in part, to agents that bind C-type lectin domain containing 9A (Clec9A) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

Abstract: The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.

Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.